Most of the following articles are available online via the NHS Scotland eLibrary. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at
If you would like to request print copies of any of the articles please contact your nearest library or visit the library website for further details.
Please note inter-library requests will only be done for South Glasgow NHS staff.
Please note, the articles you are accessing may be protected by copyright legislation, please contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the Copyright Licensing Agency at
If you have any questions regarding this or any other library services please contact your librarian.
Compiled by C. Boulnois
Library Services Manager (South)
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern GeneralHospital
1345 Govan Rd
G51 4TF
0141 201 2163
1. 10th International Symposium on the Treatment of Parkinson's Disease. Movement Disorders 2007;22.
2. Alimonti A, Bocca B, Pino A, Ruggieri F, Forte G, Sancesario G. Elemental profile of cerebrospinal fluid in patients with Parkinson's disease. Journal of Trace Elements in Medicine and Biology 2007;21:234-41.
3. Aly NM, Playfer JR, Smith SL, Halliday DM. A novel computer-based technique for the assessment of tremor in Parkinson's disease. Age & Ageing 2007;36:395-9.
4. Anderson LR, Betarbet R, Gearing M, et al. PARK10 candidate RNF11 is expressed by vulnerable neurons and localizes to Lewy bodies in Parkinson disease brain. Journal of Neuropathology & Experimental Neurology 2007;66:955-64.
5. Barichella M, Savardi C, Mauri A, et al. Diet with LPP for renal patients increases daily energy expenditure and improves motor function in Parkinsonian patients with motor fluctuations. Nutr Neurosci 2007;10:129-35.
6. Bartres-Faz D, Marti MJ, Junque C, et al. Increased cerebral activity in Parkinson's disease patients carrying the DRD2 TaqIA A1 allele during a demanding motor task: a compensatory mechanism?. Genes, Brain, & Behavior 2007;6:588-92.
7. Bhidayasiri R. How useful is (123I) beta-CIT SPECT in the diagnosis of Parkinson's disease? Reviews in Neurological Diseases 2006;3:19-22.
8. Bonuccelli U, Pavese N. Role of dopamine agonists in Parkinson's disease: An update. Expert Review of Neurotherapeutics 2007;7:1391-9.
9. Bornebroek M, De Lau LML, Haag MDM, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007;28:193-6.
10. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113:421-9.
11. Chaudhuri KR, Matrinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symtoms scle for Parkinson's disease: Results from an International Pilot Study. Movement Disorders 2007;22:1901-11.
12. Chen JJ, Fernandez HH. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs Aging 2007;24:663-80.
13. Chen LW, Wang YQ, Wei LC, Shi M, Chan YS. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS & Neurological Disorders Drug Targets 2007;6:273-81.
14. Ciccarelli O. Diffusion tensor MRI for the differentiation of Parkinson's disease and multiple system atrophy: Commentary. Nature Clinical Practice Neurology 2007;3:544-5.
15. Cohen H, Pourcher E. Intact encoding, impaired consolidation in procedural learning in Parkinson's disease. Experimental Brain Research 2007;179:703-8.
16. Cookson MR, Dauer W, Dawson T, Fon EA, Guo M, Shen J. The roles of kinases in familial Parkinson's disease. Journal of Neuroscience 2007;27:11865-8.
17. Crucian GP, Heilman K, Junco E, et al. The crossed response inhibition task in Parkinson's disease: Disinhibition hyperkinesia. Neurocase 2007;13:158-64.
18. De Letter M, Santens P, Estercam I, et al. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners. Clinical Linguistics and Phonetics 2007;21:783-91.
19. Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occupational & Environmental Medicine 2007;64:666-72.
20. Dixon L, Duncan D, Johnson P, et al. Occupational therapy for patients with Parkinson's disease.[update of Cochrane Database Syst Rev. 2001;(3):CD002813; PMID: 11687028]. Cochrane Database of Systematic Reviews 2007;:002813.
21. Earhart GM, Stevens ES, Perlmutter JS, Hong M. Perception of active and passive turning in Parkinson disease. Neurorehabil Neural Repair 2007;21:116-22.
22. Ehrt U, Bronnick K, De Deyn PP, et al. Subthreshold depression in patients with Parkinson's disease and dementia - Clinical and demographic correlates. Int J Geriatr Psychiatry 2007;22:980-5.
23. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimer's Dis 2007;11:509-19.
24. Fedorova NV, Chigir' IP. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. Neuroscience & Behavioral Physiology 2007;37:539-46.
25. Fera F, Nicoletti G, Cerasa A, et al. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease. Brain Res Bull 2007;74:75-83.
26. Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A. Noradrenaline in Parkinson's disease: From disease progression to current therapeutics. Curr Med Chem 2007;14:2330-4.
27. Forte G, Alimonti A, Violante N, Sancesario G, Brusa L, Bocca B. Metals imbalance in hair of patients affected by Parkinson's disease. Trace Elements and Electrolytes 2007;24:202-10.
28. Garske AL, Smith BC, Denu JM. Linking SIRT2 to Parkinson's disease. ACS Chemical Biology 2007;2:529-32.
29. Goldman SA. Disease targets and strategies for the therapeutic modulation of endogenous neural stem and progenitor cells. Clinical Pharmacology & Therapeutics 2007;82:453-60.
30. Goldstein DS, Imrich R, Peckham E, et al. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology 2007;69:1580-4.
31. Gomez-Esteban JC, Zarranz JJ, Tijero B, et al. Restless legs syndrome in Parkinson's disease. Movement Disorders 2007;22:1912-6.
32. Goris A, Williams-Gray CH, Clark GR, et al. Tau and a-Synuclein in susceptibility to and dementia in Parkinson's disease. Annals of Neurology 2007;62:145-53.
33. Gour J, Edwards R, Lemieux S, Ghassemi M, Jog M, Duval C. Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease. Brain Res Bull 2007;74:66-74.
34. Grotzsch H, Sztajzel R, Burkhard PR. Levodopa-induced ocular dyskinesia in Parkinson's disease. European Journal of Neurology 2007;14:1124-8.
35. Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson's disease: a review. Expert Opin Pharmacother 2007;8:2799-809.
36. Hass CJ, Collins, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair 2007;21:107-15.
37. Hausdorff JM, Lowenthal J, Herman T, Gruendlinger L, Peretz C, Giladi N. Rhythmic auditory stimulation modulates gait variability in Parkinson's disease. Eur J Neurosci 2007;26:2369-75.
38. Heisters D. Care planning for Parkinson's disease. Nurs Residential Care 2007;9:164-6.
39. Heisters D. Caring for a resident with Parkinson's disease. Nurs Residential Care 2007;9:116-8.
40. Hogl B, Gschliesser V. RLS assessment and sleep questionnaires in practice--lessons learned from Parkinson's disease. Sleep Med 2007;8:S7-12.
41. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. Journal of Nuclear Medicine 2004;45:207-13.
42. Ibanez-Sandoval O, Carrillo-Reid L, Galarraga E, et al. Bursting in substantia nigra pars reticulata neurons in vitro: Possible relevance for Parkinson disease. J Neurophysiol 2007;98:2311-23.
43. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007;69:1542-50.
44. Kashihara K, Ohno M, Kawada S, Okumura Y. Reduced cardiac uptake and enhanced washout of123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. Journal of Nuclear Medicine 2006;47:1099-101.
45. Khor S-, Hsu A. The pharmacokinetics and pharmacodynamics of Levodopa in the treatment of Parkinson's disease. Current Clinical Pharmacology 2007;2:234-43.
46. Kulkantrakorn K, Jirapramukpitak T. A prospective study in one year cumulative incidence of depression after ischemic stroke and Parkinson's disease: A preliminary study. J Neurol Sci 2007;263:165-8.
47. Kumru H, Santamaria J, Tolosa E, Iranzo A. Relation between subtype of Parkinson's disease and REM sleep behavior disorder. Sleep Med 2007;8:779-83.
48. Lawlor PA, During MJ. Gene therapy for Parkinson's disease. Expert Reviews in Molecular Medicine 2004;6:1-18.
49. Lee MA, Prentice WM, Hildreth AJ, Walker RW. Measuring symptom load in Idiopathic Parkinson's disease. Parkinsonism Relat Disord 2007;13:284-9.
50. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 2007;103:238-47.
51. Liepelt I, Maetzler W, Blaicher H, Gasser T, Berg D. Treatment of dementia in Parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cognit Disord 2007;23:351-67.
52. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007;10:1355-60.
53. Logroscino G, Sesso HD, Paffenbarger J, R.S, Lee I-. Body mass index and risk of Parkinson's disease: A prospective cohort study. Am J Epidemiol 2007;166:1186-90.
54. Louis ED, Schupf N, Tang MX, Marder K, Luchsinger JA. Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals. Archives of Neurology 2007;64:1646-51.
55. Lucchini RG, Albini E, Benedetti L, et al. High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries. Am J Ind Med 2007;50:788-800.
56. Mandel S, Amit T, Kalfon L, Youdim MBH. Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery. Expert Opinion on Drug Discovery 2007;2:1225-40.
57. Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionanaire for detecting dysphagia in patients with Parkinson's disease. Movement Disorders 2007;22:1917-21.
58. Marceglia S, Priori A. Sex, genes, hormones and nigral neurodegeneration: Two different Parkinson's diseases in males and in females. Future Neurology 2007;2:499-503.
59. Martinez-Martin P, Cubo-Delgado E, Aguilar-Barbera M, et al. A pilot study on a specific measure for sleep disorders in Parkinson's disease: SCOPA-Sleep. Rev Neurol 2006;43:577-83.
60. Martinez-Martin P, Serrano-Duenas M, Forjaz MJ, Serrano MS. Two questionnaires for Parkinson's disease: are the PDQ-39 and PDQL equivalent?. Quality of Life Research 2007;16:1221-30.
61. Masters RSW, Pall HS, MacMahon KMA, Eves FF. Duration of Parkinson disease is associated with an increased propensity for "reinvestment". Neurorehabil Neural Repair 2007;21:123-6.
62. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Virranniemi M, Myllyla VV. Postural sway and falls in Parkinson's disease: A regression approach. Movement Disorders 2007;22:1927-35.
63. Mayor S. The impact of depression on life for people with Parkinson's disease. British Journal of Neuroscience Nursing 2007;3:512-4.
64. Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-50.
65. Meral H, Aydemir T, Ozer F, et al. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease. Clin Neurol Neurosurg 2007;109:862-7.
66. Mizuno Y, Abe T, Hasegawa K, et al. Roprinirole is effective on motor function when used as an adjunct in Parkinson's disease: STRONG study. Movement Disorders 2007;22:1860-5.
67. Muller T, Welnic J, Woitalla D, Muhlack S. Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease. Neurosci Lett 2007;422:119-22.
68. Muslimovic D, Post B, Speelman JD, Schmand B. Motor procedural learning in Parkinson's disease. Brain 2007;130:2887-97.
69. Nakamura T, Hirayama M, Ito H, et al. Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 2007;263:133-8.
70. Ozben B, Bilge AK, Yilmaz E, Adalet K. Implantation of a permanent pacemaker in a patient with severe Parkinson's disease and a preexisting bilateral deep brain stimulator. International Heart Journal 2006;47:803-10.
71. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-90.
72. Perl DP, Olanow CW. The neuropathology of manganese-induced Parkinsonism. Journal of Neuropathology & Experimental Neurology 2007;66:675-82.
73. Pickering RM, Grimbergen YAM, Rigney U, et al. A meta-analysis of six prospective studes of falling in Parkinson's disease. Movement Disorders 2007;22:1892-900.
74. Post B, Merkus MP, de Hann RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: A systematic review. Movement Disorders 2007;22:1839-51.
75. Poston KL, Waters C. Zydis selegiline in the management of Parkinson's disease. Expert Opin Pharmacother 2007;8:2615-24.
76. Qutubuddin AA, Cifu DX, Armistead-Jehle P, Carne W, McGuirk TE, Baron MS. A comparison of computerized dynamic posturography therapy to standard balance physical therapy in individuals with Parkinson's disease: A pilot study. Neurorehabilitation 2007;22:261-5.
77. RamirezRuiz B, Junque C, Marti M, Valldeoriola F, Tolosa E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cognit Disord 2007;23:281-8.
78. Rentzos M, Nikolaou C, Andreadou E, et al. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurologica Scandinavica 2007;116:374-9.
79. Rodrigues JP, Walters SE, Watson P, Stell R, Mastaglia FL. Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease. Movement Disorders 2007;22:1866-70.
80. Romigi A, Stanzione P, Marciani MG, et al. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. J Neural Transm 2006;113:1909-13.
81. Rosen AR, Steenland NK, Hanfelt J, Factor SA, Lah JJ, Levey AI. Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history. Neurogenetics 2007;8:263-70.
82. Samii A, Slimp JC, Friedly JL, Goodkin R. Spinal accessory neuropathy after deep brain stimulation for Parkinson's disease. Stereotactic & Functional Neurosurgery 2007;85:296-8.
83. Samii A, Slimp JC, Friedly JL, Goodkin R. Spinal accessory neuropathy after deep brain stimulation for parkinson's disease. Stereotact Funct Neurosurg 2007;85:296-8.
84. Sapir S, Spielman JL, Ramig LO, Story BH, Fox C. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: Acoustic and perceptual findings. Journal of Speech, Language, and Hearing Research 2007;50:899-912.
85. Sauermann S, Standhardt H, Gerschlager W, Lanmuller H, Alesch F. Kinematic evaluation in Parkinson's disease using a hand-held position transducer and computerized signal analysis. Acta Neurochir 2005;147:939-45.
86. Schadt CR, Cox KL, Tramontana MG, et al. Depression and intelligence in patients with Parkinson's disease and deep-brain stimulation. J Natl Med Assoc 2006;98:1121-5.
87. Schwarz J, Storch A, Koch W, Pogarell O, RadauPE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. Journal of Nuclear Medicine 2004;45:1694-7.
88. Schweitzer KJ, Brussel T, Leitner P, et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 2007;254:613-6.
89. Seeberger LC, Hauser RA. Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacology 2007;53:791-800.
90. Seijo FJ, Alvarez-Vega MA, Gutierrez JC, Fdez-Glez F, Lozano B. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochir 2007;149:867-75.
91. Siddiqui MAA, Wagstaff AJ. Rivastigmine in Parkinson's disease dementia: profile report. Drugs Aging 2007;24:255-9.
92. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agents. Movement Disorders 2007;22:1936-42.
93. Simonson W, Hauser RA, Schapira AH. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. Ann Pharmacother 2007;41:1842-9.
94. Simonson W, Hauser RA, Schapira AHV. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. Ann Pharmacother 2007;41:1842-9.
95. Staines DR. Is Parkinson's disease an autoimmune disorder of endogenous vasoactive neuropeptides?. Med Hypotheses 2007;69:1208-11.
96. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006;7:1399-407.
97. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1-25.
98. Taylor JM, Song YJ, Huang Y, et al. Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases. Neurobiol Dis 2007;27:238-47.
99. Timmermann L, Florin E, Reck C. Pathological cerebral oscillatory activity in Parkinson's disease: A critical review on methods, data and hypotheses. Expert Review of Medical Devices 2007;4:651-61.
100. Tsai S-. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects. Med Hypotheses 2007;69:1219-21.
101. Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierckx R. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: Correlation with clinical parameters. Journal of Nuclear Medicine 2004;45:933-42.
102. Wallin A, Ekberg S, Lind K, Milos V, Granerus A, Granerus G. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease - a rCBF scintigraphy study. Acta Neurologica Scandinavica 2007;116:347-54.
103. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between Parkinsonism and idiopathic Parkinson Disease. Archives of Neurology 2007;64:1635-40.
104. Wang H-, Chou A-, Yeh T-, et al. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 2007;28:216-26.
105. Wang X-, Zhao Y-, Lassonde M, Geng C-. A pilot study of procedural learning in patients with non-demented Parkinson's disease. Neuroscience Bulletin 2005;21:291-5.
106. Weiner WJ. Motor fluctuations in Parkinson's disease. Reviews in Neurological Diseases 2006;3:101-8.
107. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 2007;164:1491-8.
108. Weintraub D, Xie S, Karlawish J, Siderowf A. Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: Evidence from the 15-item Geriatric Depression Scale (GDS-15). Int J Geriatr Psychiatry 2007;22:1025-30.
109. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-7.
110. Weng Y-, Yen T-, Chen M-, et al. Sensitivity and specificity of99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. Journal of Nuclear Medicine 2004;45:393-401.
111. Willems A, Nieuwboer A, Chavret F, et al. Turning in Parkinson's disease patients and controls: The effect of auditory cues. Movement Disorders 2007;22:1871-8.
112. Winkler S, Konig IR, Lohmann-Hedrich K, Vieregge P, Kostic V, Klein C. Role of ethnicity on the association of MAPT H1 haplotypes and subhaplotypes in Parkinson's disease. European Journal of Human Genetics 2007;15:1163-8.
113. Worth PF. A perspective on the current issues in the diagnosis of Parkinson's disease. Br J Hosp Med 2007;68:S6.
114. Wright WG, Gurfinkel VS, Nutt J, Horak FB, Cordo PJ. Axial hypertonicity in Parkinson's disease: Direct measurements of trunk and hip torque. Exp Neurol 2007;208:38-46.
115. Wu AD. Functional neuroimaging and repetitive transcranial magnetic stimulation in Parkinson's disease. Reviews in Neurological Diseases 2007;4:1-9.
116. Yogev G, Plotnik M, Peretz C, Giladi N, Hausdorff JM. Gait asymmetry in patients with Parkinson's disease and elderly fallers: when does the bilateral coordination of gait require attention?. Experimental Brain Research 2007;177:336-46.
117. Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Annals of Neurology 2007;62:137-44.
If you would like to receive additional bulletin, please tick the bulletins you would like to receive, ensure your name and address are on the front cover and return to the library address given overleaf.
A&E / Healthcare Associated InfectionAllied Health Professionals / Healthy Heart
Alzheimer’s disease / IT
Ambulatory care / Lung Cancer
Anaesthesia / Medicine for the Elderly
Asthma / Multiple Sclerosis
Burns/Dermatology/Plastics / Neonatal Nursing and Midwifery
Cancer: Pain / New Books
Cancer Supportive Care / New Books (all sites & Nursing)
Chaplain / New Nurse
Child Protection / Nutrition
Clinical Governance / Orthopaedics
Community Child Health / Paediatric Anaesthesia & Pain
Community Nursing / Paediatric Oncology Nursing
Complaints / Paediatric Physiotherapy
Coronary Intensive and High Dependency Care / Paediatric Respiratory Medicine
Corporate Services / Parkinson’s disease
Day surgery / Pharmacy
Dental Care Professionals / Prevention & Treatment of Alcohol & Drug Abuse (Nursing)
Dentistry / Primary Care Mental Health
Digestive Diseases / Rheumatology
Elderly Care Bulletin (Nursing) / Sarcoma
Epilepsy / School nurses
Guidelines / Speech and Language Therapy
Gynaecologic Oncology / Spinal Injuries
Head Injury / Stroke (North Glasgow)
Health Promotion / Stroke (South Glasgow)
Training, education and Management (Nursing)
How to Access Electronic Articles
Many of the articles in this bulletin will be available online at the NHS Scotland eLibrary